First drug to demonstrate clinical symptomatic efficacy for typical Omicron-related symptoms and antiviral efficacy.
SINGAPORE, Dec. 22, 2023 /PRNewswire/ — Singapore-based Juniper Therapeutix, a science-based healthcare company focused on commercializing novel therapies, announced its agreement with Ping-An Shionogi Hong Kong, a Shionogi Group company
Ensitrelvir is an antiviral drug for COVID-19 that has already been approved under the emergency regulatory approval system in Japan. The drug is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease. It is the first antiviral drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy in patients with a mild to moderate SARS-CoV-2 infection.
“While the severity of COVID-19 has decreased, it remains a cause for concern, underscoring the continued importance of prioritizing preparedness and proactive physical care. Ensitrelvir is a critical tool for effective case management, offering an extra layer of care and attention in our ongoing fight against this ever-evolving virus,” said Raman Singh, CEO of Juniper Biologics. “By partnering with Shionogi, we are proud to enable access to Ensitrelvir. This unmanageable curative drug will go a long way toward helping inflamed COVID-19 patients recover. and return to your general life.
Shionogi Group, adding Ping An-Shionogi Hong Kong, will continue to work intensively with Juniper Therapeutics to provide the necessary approval and advertising publication in Singapore under the existing agreement.
About fumaric acid ensitrelvir
Ensitrelvir (code number: S-217622), a COVID-19 antiviral drug recently approved under the emergency regulatory approval formula in Japan, is a 3CL protease inhibitor created through joint studies between Hokkaido University and Shionogi. SARS-CoV-2 has an enzyme called 3CL protease that is responsible for virus replication. Ensitrelvir suppresses SARS-CoV-2 replication by selectively inhibiting the 3CL protease. Ensitrelvir is the first antiviral agent to show clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy in patients with mild to moderate SARS-CoV-2 infection, regardless of threat points or vaccination status. Shionogi has a comprehensive global clinical progression program underway for Ensitrelvir that includes 4 Phase 3 trials, in addition to SCORPIO-HR, a trial for symptomatic non-hospitalized COVID-19 patients who have tested positive for COVID-19. SCORPIO-HR is also comparing the prospective effect of Ensitrelvir on long COVID symptoms. A review of investigator-initiated studies in hospitalized patients for the control of COVID-19 is also underway under the new Strategies and Treatments for Respiratory Infections and Viral Emergencies (STRIVE) platform protocol. Additionally, Shionogi’s study, SCORPIO-PEP, compares the protection and efficacy of Ensitrelvir for the prevention of symptomatic SARS-CoV-2 infection in study participants exposed to symptomatic household contacts who tested positive for SARS-CoV -2.
About Juniper Therapeutics
Juniper Therapeutics is a partner of Juniper Biologics. Backed through Sylvan Group, Juniper Biologics is a science-based, specialty healthcare company based in Singapore and dedicated to the commercialization of novel treatments. Founded with a vision to deliver the next generation of innovative treatments to address unmet needs, the company specializes in healing spaces that can make the biggest difference: oncology and supportive cancer care, rare/orphan diseases, and gene therapy. To learn more about Juniper Biologics and its portfolio, visit https://www. juniperbiologics. com/.
About Ping An-Shionogi
Ping An-Shionogi Hong Kong was established in 2020 as a joint venture between Shionogi Hong Kong and Tutum Japan Healthcare Limited, a subsidiary of China Ping An Insurance Overseas (Holdings) Limited and an indirect subsidiary of Ping An Insurance (Group) Company of China. Ltd. ‘s main activities are capital investment, intellectual asset licensing management, and product origin operations in Asian countries.
About Shionogi
Shionogi
For more information about Shionogi
SOURCE Organic Juniper Products
Stay Informed
AAP FactCheck provides factual, authoritative information Australians can rely on. Accredited with the Poynter Institute’s International Fact-Checking Network and adhering to the highest industry standards, our experienced team works to minimise the impact of misinformation.
Image buyers from all industries rely on AAP Photos. A digital treasure trove of content depicting Australian life, our fully-searchable database contains millions of images from around the country and around the world.
AAPNews delivers news content directly to the public. Choose from a variety of subscription templates to not only access high-quality factual data on your computer or mobile device, but also to display your information on Australia’s only not-for-profit news service.
Get the news your organization needs, with AAP providing comprehensive news, court, politics, sports, finance, and arts policy. Leverage content from AAP partners to get the global news that matters to your business, with news feeds delivered across channels, adding APIs, and FTP.
AAP is Australia’s only independent newswire service, delivering stories and images around the country and around the world every day. By supporting AAP with your contribution you are backing a team of dedicated, objective journalists to continue this work. Thank you.
Donations over $2 are tax deductible.